Samaritan gets grant for Alzheimer's blood test
This article was originally published in Clinica
Samaritan Pharmaceuticals and Georgetown University, are to develop a simple blood test for predicting Alzheimer's disease using a $188,000 grant from the US National Institutes of Health. The test will be based on detecting the detecting the increase of the hormone dehydroepiandrosterone (DHEA). Researchers from the Las Vegas, Nevada firm's Samaritan Research Laboratories, at Georgetown University, recently discovered a potential correlation between DHEA precursor levels in blood plasma, and Alzheimer's disease. Using the new funds, researchers plan to differentiate between the levels of DHEA precursor in the plasma of patients with and without the disease, and to define the relationship between the levels of DHEA precursor, in plasma, and Alzheimer's.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.